BofA raised the firm’s price target on Alignment Healthcare (ALHC) to $13 from $11 and keeps a Buy rating on the shares after outperformance in Q3 on revenue growth, SG&A leverage, and absolute profit ...
Stifel analyst Craig Jones raised the firm’s price target on Alignment Healthcare (ALHC) to $18 from $16 and keeps a Buy rating on the shares. Revenue continues to outperform on strong new member adds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback